Loading organizations...
§ Private Profile · Providence, RI, USA
Biotechnology company developing antisense oligonucleotide therapeutics to promote neurogenesis for Alzheimer's, stroke, and depression.
Bolden Therapeutics is a Providence, Rhode Island-based biotechnology company developing targeted antisense oligonucleotide therapeutics to promote neurogenesis for the treatment of central nervous system disorders. The enterprise targets a novel signaling pathway to stimulate the formation of new brain cells, addressing severe neurological conditions such as Alzheimer’s disease, treatment-resistant depression, and ischemic stroke recovery. Operating with fewer than 25 employees and generating under $5 million in estimated annual revenue, the firm has successfully demonstrated preclinical proof-of-concept in various laboratory mouse models. To finance its extensive research and development pipeline toward upcoming human clinical trials, the business has secured capital from private investors and public entities, including the National Institutes of Health and the University of Chicago Innovation Fund. Bolden Therapeutics was officially founded in 2022 by Johnny Page, Justin Fallon, and Eric Webb.
Bolden Therapeutics has raised $1.5M across 1 funding round.
Bolden Therapeutics has raised $1.5M in total across 1 funding round.
Bolden Therapeutics has raised $1.5M in total across 1 funding round.
Bolden Therapeutics's investors include Resolute Venture Partners, Andrew Worden, Slater Technology Fund.
Bolden Therapeutics has raised $1.5M across 1 funding round. Most recently, it raised $1.5M Pre-Seed in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 22, 2024 | $1.5M Pre Seed | Resolute Venture Partners | Andrew Worden, Slater Technology Fund | Announced |